A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats
Open Access
- 22 July 2022
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 19 (6) , 647-654
Abstract
Background: The threat of a possible Marburg virus disease outbreak in Central and Western Africa is growing. While no Marburg virus vaccines are currently available for use, several candidates are in the pipeline. Building on knowledge and experiences in the designs of vaccine efficacy trials against other pathogens, including SARS-CoV-2, we develop designs of randomized Phase 3 vaccine efficacy trials for Marburg virus vaccines. Methods: A core protocol approach will be used, allowing multiple vaccine candidates to be tested against controls. The primary objective of the trial will be to evaluate the effect of each vaccine on the rate of virologically confirmed Marburg virus disease, although Marburg infection assessed via seroconversion could be the primary objective in some cases. The overall trial design will be a mixture of individually and cluster-randomized designs, with individual randomization done whenever possible. Clusters will consist of either contacts and contacts of contacts of index cases, that is, ring vaccination, or other transmission units. Results: The primary efficacy endpoint will be analysed as a time-to-event outcome. A vaccine will be considered successful if its estimated efficacy is greater than 50% and has sufficient precision to rule out that true efficacy is less than 30%. This will require approximately 150 total endpoints, that is, cases of confirmed Marburg virus disease, per vaccine/comparator combination. Interim analyses will be conducted after 50 and after 100 events. Statistical analysis of the trial will be blended across the different types of designs. Under the assumption of a 6-month attack rate of 1% of the participants in the placebo arm for both the individually and cluster-randomized populations, the most likely sample size is about 20,000 participants per arm. Conclusion: This event-driven design takes into the account the potentially sporadic spread of Marburg virus. The proposed trial design may be applicable for other pathogens against which effective vaccines are not yet available.Keywords
Funding Information
- Medical Research Council (PR-OD-1017-20007)
- National Institute of Allergy and Infectious Diseases (R01 AI 139761)
- National Institute of Allergy and Infectious Diseases (R01 AI136947)
- National Institute of Allergy and Infectious Diseases (R37 AI 29168)
This publication has 19 references indexed in Scilit:
- The use of permutation tests for the analysis of parallel and stepped‐wedge cluster‐randomized trialsStatistics in Medicine, 2017
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)The Lancet, 2017
- On the estimation of intracluster correlation for time-to-event outcomes in cluster randomized trialsStatistics in Medicine, 2016
- After Ebola in West Africa — Unpredictable Risks, Preventable EpidemicsNew England Journal of Medicine, 2016
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trialThe Lancet, 2015
- Sample size in cluster‐randomized trials with time to event as the primary endpointStatistics in Medicine, 2012
- On the relative efficiency of using summary statistics versus individual-level data in meta-analysisBiometrika, 2010
- Design and sample size estimation in clinical trials with clustered survival times as the primary endpointStatistics in Medicine, 2003
- Survival Analysis in Clinical Trials: Past Developments and Future DirectionsBiometrics, 2000
- Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations1992